A first-in-class Polymerase Theta Inhibitor selectively targets Homologous-Recombination-Deficient Tumors

DNA polymerase theta (POLθ) is synthetic lethal with Homologous Recombination (HR) deficiency and thus a candidate target for HR-deficient cancers. Through high-throughput small molecule screens we identified the antibiotic Novobiocin (NVB) as a specific POLθ inhibitor that selectively kills HR-defi...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Jia, Gelot, Camille, Pantelidou, Constantia, Li, Adam, Yücel, Hatice, Davis, Rachel E., Farkkila, Anniina, Kochupurakkal, Bose, Syed, Aleem, Shapiro, Geoffrey I., Tainer, John A., Blagg, Brian S. J., Ceccaldi, Raphael, D’Andrea, Alan D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8224818/
https://www.ncbi.nlm.nih.gov/pubmed/34179826
http://dx.doi.org/10.1038/s43018-021-00203-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8224818/
https://www.ncbi.nlm.nih.gov/pubmed/34179826
http://dx.doi.org/10.1038/s43018-021-00203-x

Ejemplares similares